Immunization with recombinant transferrin binding protein B enhances clearance of nontypeable Haemophilus influenzae from the rat lung.
Nontypeable Haemophilus influenzae (NTHI) is an opportunistic pathogen, and heterogeneity in the surface-exposed immunodominant domains of NTHI proteins is thought to be associated with the failure of an infection to stimulate an immune response that is cross-protective against heterologous NTHI strains. The aim of this study was to assess the vaccine potential of a surface-exposed component of the NTHI human transferrin receptor, TbpB, and to determine if the antibody response elicited was cross-reactive with heterologous strains of NTHI. The efficacy of immunization with a recombinant form of TbpB (rTbpB) was determined by assessing the pulmonary clearance of viable bacteria 4 h after a live challenge with NTHI. There was a significant reduction in the number of viable bacteria in both the bronchoalveolar lavage fluid (34% for the 20-microgram dose and 58% for the 40-microgram dose) and lung homogenates (26% for the 20-microgram dose and 60% for the 40-microgram dose) of rats immunized with rTbpB compared to the control animals. While rTbpB-specific antibodies from immunized rats were nonspecific in the recognition of TbpB from six heterologous NTHI strains on Western blots, these antibodies differed in their ability to block transferrin binding to heterologous strains and to cross-react in bactericidal assays. If bactericidal antibodies are key indicators of the efficacy of the immune response in eliminating NTHI, this data suggests that while immunization with rTbpB stimulates protective responses against the homologous isolate, variability in the recognition of TbpB from heterologous isolates may limit the potential of rTbpB as an NTHI vaccine component.
Webb
D C
DC
Gadi Research Centre, Faculty of Applied Science, University of Canberra, Canberra City, ACT 2601, Australia. Dianne.Webb@anu.edu.au
Cripps
A W
AW
D000595:Amino Acid Sequence; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology; D001483:Base Sequence; D002352:Carrier Proteins / Q000235:genetics / Q000276:immunology*; D003429:Cross Reactions; D017931:DNA Primers / Q000235:genetics; D006192:Haemophilus Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D006193:Haemophilus influenzae / Q000145:classification / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D018928:Immunity, Mucosal; D007114:Immunization; D033862:Iron-Binding Proteins; D008168:Lung / Q000382:microbiology*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D011990:Receptors, Transferrin / Q000235:genetics / Q000276:immunology*; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D012141:Respiratory Tract Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D033882:Transferrin-Binding Protein B; D033863:Transferrin-Binding Proteins
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D002352:Carrier Proteins; D017931:DNA Primers; D033862:Iron-Binding Proteins; D011990:Receptors, Transferrin; D011994:Recombinant Proteins; D033882:Transferrin-Binding Protein B; D033863:Transferrin-Binding Proteins